中西医结合治疗支气管肺炎临床疗效及经济分析

Clinical efficacy and economic analysis of combined treatment with Chinese and Western medicine for pediatric bronchopneumonia

目的总结中西医结合治疗小儿支气管肺炎的临床疗效及经济费用,为本病患儿的治疗方案提供依据。方法将120例诊断为细菌感染的支气管肺炎的患儿随机分为观察组和对照组两组,每组60例。所有患儿均给予抗生素、退热等西医常规治疗,在此基础上观察组给予改良的强元肃肺汤,对照组60例给予等量的红糖水。监测两组患儿症状、体征的改善、住院时间和治疗费用等指标,以及两组患儿治疗第7天和第10天的临床疗效。结果观察组在发热、气促、咳嗽和啰音消失时间及住院时间等指标均优于对照组,两组比较差异有统计学意义(P<0.01);观察组第7天的治愈率为61.6%,对照组为41.6%;观察组总有效率为91.6%,对照组为76.6%,两组治愈率和总有效率比较,差异有统计学意义(P<0.05)。观察组第10天的治愈率为81.6%,而对照组治愈率为68.3%,两组比较差异无统计学意义(P>0.05)。观察组人均住院费用(2 327±197)元,对照组(2 959±284)元,观察组较对照组节省21.35%,两组比较差异有统计学意义(P<0.01)。结论中西医结合治疗小儿支气管肺炎能提高临床疗效和治愈率,缩短治疗时间并节省费用,值得临床推广。

Objective Study of the therapeutic efficiency of the combinational treatment of Chinese-Western medicine for pediatric bronchopneumonia. Method 120 of pediatric bronchopneumonia patients were divided into two groups randomly, 60 cases for each group. Group one was treated with both Chinese and Western medicine and group two was treated with Western medicine only. The group one had antibiotics and modified Chinese herbal formula Qiang yuan su fei; the group two was given antibiotics and drinking water with brown sugar added. Both were monitored during hospitalization period, and the clinical curative effect of seventh and tenth days were reviewed. Results Significant difference between the two groups in the improvement of symptoms, signs and hospitalization time（P〈0.01）. In seventh day the cure rate of the group one was 61.6%, the total effective rate was 91.6%, significantly better than the group two with the cure rate of 41.6%and 76.6% of the total efficiency （P〈0.05）. In tenth day the cure rate of the group one was 81.6%, the cure rate of the group two of 68.3% at the same time, the group one was slightly better than the group two, but the difference was not statistically significant （P〈0.05）. The group one per capita cost 632 yuan, compared with the group two of 21.35% reduction（P〈0.0l）. Conelnsion The combinational treatment with both Chinese and Western medicine for pediatric bronchopneumonia can improve the clinical curative effect and cure rate, shorten the treatment time and cost savings.